NASDAQ : AVIR
Atea Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 345.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 329.64M |
| Enterprise Value | 110.60M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 80.20M |
| Shares Outstanding | 80.20M |
| Shares Change (YoY) | -6.62% |
| Shares Change (QoQ) | +1.08% |
| Owned by Insiders (%) | 16.10% |
| Owned by Institutions (%) | 67.94% |
| Float | 60.34M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.61 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.13 |
| Quick Ratio | 7.80 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -58.14% |
| Return on Assets (ROA) | -36.72% |
| Return on Invested Capital (ROIC) | -40.17% |
| Return on Capital Employed (ROCE) | -89.77% |
| Weighted Average Cost of Capital (WACC) | 6.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.01M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -6.50M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +24.92% |
| 50-Day Moving Average | 5.04 |
| 200-Day Moving Average | 4.93 |
| Relative Strength Index (RSI) | 32.30 |
| Average Volume (20 Days) | 301,330 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.07M |
| Short Previous Month | 7.89M |
| Short % of Shares Out | 3.83% |
| Short % of Float | 5.09% |
| Short Ratio (days to cover) | 10.36 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -155.12M |
| Operating Income | -183.27M |
| Pretax Income | -171.79M |
| Net Income | -165.29M |
| EBITDA | -182.86M |
| EBIT | -183.27M |
| Earnings Per Share (EPS) | -$2.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 219.47M |
| Total Debt | 424,000 |
| Net Cash | 219.04M |
| Net Cash Per Share | $2.73 |
| Equity (Book Value) | 204.16M |
| Book Value Per Share | 2.55 |
| Working Capital | 200.54M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -152.07M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 416,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -152.07M |
| FCF Per Share | -$1.90 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 6.62% |
| Shareholder Yield | 6.62% |
| Earnings Yield | -51.00% |
| FCF Yield | -46.13% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.50 |
| Price Target Difference | 106.81% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |